Incannex Healthcare Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2024, the company’s fiscal third quarter (fiscal year ends June 30). The request metadata says “2023 Q3,” but the filing covers 2024 Q3. Unless noted otherwise, financial amounts below are U.S. dollars in millions.
Business context and financial position
Incannex is an early-stage drug-development company focused on psychedelic medicines and therapies for mental health disorders. It reports one operating segment and has not reported product revenue. The filing reflects the November 2023 redomiciliation from Australia to Delaware; historical financial statements were recast to U.S. GAAP and the new share structure.
- Cash and cash equivalents were $9.305 million at March 31, 2024, down from $22.120 million at June 30, 2023. Total assets were $17.250 million; total liabilities were $3.112 million.
- Current assets were $16.319 million and current liabilities were $2.864 million. Liabilities included $0.409 million of operating lease obligations; the filing reports no borrowings or credit facility.
- Cash used in operating activities was $12.203 million for the nine months; investing cash use was $0.274 million, with no financing proceeds. Cash decreased by $12.477 million, including currency effects.
Results and changes versus comparable periods
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 | Nine months ended March 31, 2024 | Nine months ended March 31, 2023 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $3.277m | $1.639m | $8.520m | $4.597m |
| General and administrative expense | $4.138m | $2.012m | $11.777m | $5.530m |
| Total operating expense | $7.415m | $3.651m | $20.297m | $45.474m |
| Net loss | $6.031m | $3.571m | $11.998m | $44.637m |
| Net loss per share | $0.38 | $0.22 | $0.76 | $2.93 |
Quarterly R&D expense rose 100%, which management attributed mainly to clinical research and product development. Nine-month R&D expense rose 85%, reflecting trials including IHL-42X bioequivalence/bioavailability work and an obstructive sleep apnea study, and an IHL-675A rheumatoid arthritis study. G&A increased, including from higher employee costs, share-based compensation and post-redomiciliation legal, accounting and compliance costs. The prior-year nine-month loss included $35.347 million of acquired in-process R&D expense for the APIRx asset acquisition, explaining much of the year-over-year reduction in total operating expense and net loss.
The company recorded $8.150 million of R&D tax incentive income in the nine-month period versus $0.684 million a year earlier, and reported a $6.406 million R&D tax credit receivable at March 31. During the December 2023 quarter, it changed its estimate of the incentive receivable, increasing the receivable and other income by approximately $5 million. No income tax expense was recorded. Foreign-currency translation losses were $0.820 million for the quarter and $0.403 million for the nine months.
Outlook, risks and other notable items
- Management said available cash was expected to fund operations at least until December 2024, while noting the estimate is uncertain. It expects substantial additional funding will be needed for long-term development and anticipates continued losses.
- Management does not expect significant revenue before regulatory approval and commercialization. The filing provides no formal financial guidance or specific trial timelines.
- Key risks include securing future financing, successful and timely clinical development, regulatory approval and market acceptance, reliance on third-party research and manufacturing providers, intellectual property protection, competition, and retaining personnel.
- Management concluded disclosure controls were effective as of March 31, 2024, and reported no material change in internal control during the quarter. The company reported no material legal proceedings.
- Common shares outstanding were 15,873,113 at March 31, 2024 and May 15, 2024. The filing’s fully converted share-capital table reports 19,590,674 shares, including restricted stock and warrants.
Important facts for investors to verify
- Cash runway assumptions and the timing and availability of additional financing, given $12.203 million of operating cash use over nine months and $9.305 million of cash remaining.
- Collection, eligibility and timing of the $6.406 million R&D tax credit receivable, including the approximately $5 million estimate change.
- Clinical-trial progress, costs and funding requirements for IHL-42X, IHL-675A and other candidates.
- The filing’s MD&A describes the year-over-year R&D tax credit benefit as having “decreased,” while its financial statements show $8.150 million for the 2024 nine-month period versus $0.684 million for 2023; investors may wish to reconcile this wording with the reported amounts.
- Potential dilution: review the terms and vesting of restricted stock, warrants and options alongside the filing’s fully converted share count.